SCHEMBL6818404

SCHEMBL6818404

CC(C)n1nc(-c2c(-c3ccccc3)nn3ccc(OCc4ccncc4)cc23)ccc1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.40
ABL1 P00519 2/20 0.40
CMKLR1 Q99788 1/20 0.39
ADORA1 P30542 2/20 0.39
CYP19A1 P11511 3/20 0.35
PDE4B Q07343 1/20 0.35
MAPK14 Q16539 1/20 0.35
MCHR1 Q99705 2/20 0.35
KCNH2 Q12809 2/20 0.35
ADORA2A P29274 1/20 0.34
EGFR P00533 1/20 0.34
RAF1 P04049 1/20 0.34
CYP3A4 P08684 1/20 0.34
ARAF P10398 1/20 0.34
BRAF P15056 1/20 0.34
KDR P35968 1/20 0.34
MAP2K2 P36507 1/20 0.34
FLT3 P36888 1/20 0.34
ERBB4 Q15303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822608 0.95 CMKLR1 (0.41) SRCABL1CMKLR1ADORA1MAPK14
SCHEMBL6821500 0.91 CMKLR1 (0.38) CMKLR1ADORA1
SCHEMBL6822483 0.90 CMKLR1 (0.42) SRCABL1CMKLR1ADORA1CYP19A1
SCHEMBL6821534 0.88 ADORA1 (0.39) CMKLR1ADORA1MCHR1CYP3A4
SCHEMBL6821458 0.87 ADORA1 (0.39) CMKLR1ADORA1MAPK14ADORA2AEGFR
SCHEMBL6822058 0.87 ADORA1 (0.42) SRCABL1CMKLR1ADORA1ADORA2A
SCHEMBL6822100 0.86 ADORA1 (0.40) CMKLR1ADORA1MCHR1KCNH2
SCHEMBL6822546 0.85 ADORA1 (0.41) SRCABL1CMKLR1ADORA1EGFR
SCHEMBL6824716 0.85 ADORA1 (0.40) CMKLR1ADORA1ADORA2A
SCHEMBL6818702 0.85 ADORA1 (0.46) CMKLR1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 SRC 1011/4885ABL1 2274/4885CMKLR1 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.